Scarica l'app Stockscreener
0.5674
18.91%
-0.1323
Pre-mercato:
.56
-0.0074
-1.30%
Precedente Chiudi:
$0.6997
Aprire:
$0.6427
Volume 24 ore:
9.03M
Relative Volume:
1.52
Capitalizzazione di mercato:
$19.47M
Reddito:
-
Utile/perdita netta:
$-22.83M
Rapporto P/E:
-0.7182
EPS:
-0.79
Flusso di cassa netto:
$-20.87M
1 W Prestazione:
+40.10%
1M Prestazione:
+78.88%
6M Prestazione:
-25.43%
1 anno Prestazione:
-68.99%
Intervallo 1D:
$0.56
$0.6648
Intervallo di 1 settimana:
$0.4306
$1.04
Portata 52W:
$0.2223
$2.535
Cognition Therapeutics Inc Stock (CGTX) Company Profile
Nome
Cognition Therapeutics Inc
Settore
Industria
Telefono
412-481-2210
Indirizzo
2403 SIDNEY STREET, PITTSBURGH
Confronta CGTX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CGTX
Cognition Therapeutics Inc
|
0.5674 | 19.47M | 0 | -22.83M | -20.87M | -0.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.85 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.94 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
560.24 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
250.30 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Cognition Therapeutics Inc Stock (CGTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-19 | Aggiornamento | B. Riley Securities | Neutral → Buy |
| 2024-07-30 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2021-11-03 | Iniziato | B. Riley Securities | Buy |
| 2021-11-03 | Iniziato | Oppenheimer | Outperform |
Cognition Therapeutics Inc Borsa (CGTX) Ultime notizie
Cognition Therapeutics: Clinical Milestones Ignite Potential in Neurodegenerative Therapeutics - AInvest
Cognition Therapeutics, Inc. (CGTX) Retains Buy Rating on START Study Progress - Yahoo
Cognition Therapeutics shares fall 10.57% in premarket after FDA meeting on zervimesine for Alzheimer's treatment. - AInvest
Cognition Therapeutics completes FDA end-of-Phase 2 meeting for Alzheimer’s drug By Investing.com - Investing.com South Africa
Cognition Therapeutics Inc. (CGTX) Soars 31.45% on FDA Phase 3 Trial Approval - AInvest
Cognition soars 35% after positive FDA meeting on Alzheimer's asset zervimesine - Seeking Alpha
Cognition Therapeutics stock soars after FDA meeting on Alzheimer’s drug - Investing.com
Cognition Therapeutics Conducts Meeting With US FDA to Review Phase 2 Study Results of Zervimesine - MarketScreener
Cognition Therapeutics Soars 61.65% on Positive FDA Meeting - AInvest
Cognition Therapeutics: Zervimesine Emerges as Alzheimer's Breakthrough with FDA Backing and NIH Support - AInvest
Cognition Therapeutics, Inc. Discusses Phase 2 Results and Future Plans for Zervimesine Treatment in Alzheimer's Disease with FDA - Nasdaq
Cognition Therapeutics Completes End-of-Phase 2 Meeting with FDA for Zervimesine (CT1812) in Alzheimer’s Disease - GlobeNewswire
Breakthrough for Alzheimer's Treatment: FDA Meeting Clears Path for Zervimesine Phase 3 Program - Stock Titan
Cognition Therapeutics (CGTX) Soars 12% After-Hours on Alzheimer's Trial Data - AInvest
CGTX Soars 11.11% on Clinical Trial Progress, Analyst Optimism - AInvest
Cognition Therapeutics stock maintains Buy rating as Phase 2 trial reaches 50% enrollment - Investing.com Canada
Breakthrough Alzheimer's Drug Zervimesine Achieves 95% EfficacyPhase 2 Trial Hits Major Milestone - Stock Titan
Cognition Therapeutics Advances with CT1812 in Dementia Study - TipRanks
Cognition Therapeutics Faces a Clock Running Out: Cash Crisis and the Race for Survival - AInvest
Alzheimer’s Disease Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, and Pipeline Analysis | AriBio Co., Ltd., Eli Lilly & Co., Cognition Therapeutics, AbbVie Inc - Barchart.com
Cognition Therapeutics Provides Regulatory Update on Zervimesine (CT1812) in Alzheimer’s Disease and Dementia with Lewy Bodies (DLB) - Yahoo Finance
Cognition Therapeutics Holds Virtual Annual Stockholders Meeting - TipRanks
Cognition Therapeutics, Inc. (NASDAQ:CGTX) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Two Sigma Investments LP Boosts Stock Position in Cognition Therapeutics, Inc. (NASDAQ:CGTX) - Defense World
Safety scares and trial misses drag down neuro biotechs into Q2 - BioWorld MedTech
Cognition Therapeutics (CGTX) Secures Donation to Support Dement - GuruFocus
Cognition Therapeutics Launches Expanded Access Program for Zervimesine - TipRanks
Cognition Therapeutics Announces Expanded Access Program for Dementia with Lewy Bodies, Led by Dr. James Galvin - Nasdaq
Philanthropic Donor Funds Cognition Therapeutics’ Expanded - GlobeNewswire
Major Breakthrough: Donor Funds New Treatment Access for Lewy Body Dementia Patients - Stock Titan
B. Riley Expects Reduced Earnings for Cognition Therapeutics - Defense World
HC Wainwright Issues Positive Forecast for CGTX Earnings - Defense World
Alzheimer's Disease Pipeline 2025: MOA and ROA Insights, - openPR.com
Cognition Therapeutics (NASDAQ:CGTX) Price Target Cut to $3.00 by Analysts at HC Wainwright - Defense World
Cognition Therapeutics Releases New Episode of - GlobeNewswire
Lewy Body Dementia Caregivers Share Powerful Stories Alongside Leading Neurologists in New Medical Podcast - Stock Titan
Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Studying the Patient/Caregiver Lived Experience in Dementia with Lewy Bodies - GlobeNewswire
CGTX: HC Wainwright & Co. Lowers Price Target While Maintaining Buy Rating | CGTX Stock News - GuruFocus
Cognition Therapeutics (CGTX) Sees Reduced Price Target Amid Exp - GuruFocus
Cognition Therapeutics (CGTX) Sees Reduced Price Target Amid Expected Equity Dilution | CGTX Stock News - GuruFocus
Cognition stock target cut to $3 by H.C. Wainwright, retains Buy - Investing.com
Cognition Therapeutics, Inc. (NASDAQ:CGTX) Receives Average Recommendation of “Buy” from Brokerages - Defense World
Chardan Capital Issues Pessimistic Forecast for Cognition Therapeutics (NASDAQ:CGTX) Stock Price - Defense World
Cognition Therapeutics Presents Preclinical Data On Zervimesine, Stock Down - Nasdaq
Cognition announces outcomes from trial of zervimesine for geographic atrophy - Yahoo Finance
Cognition Therapeutics Inc (NASDAQ: CGTX) Stock Price Forecast: $100 - Stocksregister
Cognition Therapeutics Reports Promising Preclinical Data for Zervimesine in Protecting RPE Cells from Dry AMD at ARVO 2025 - Nasdaq
Cognition Therapeutics Presented Data at Association for - GlobeNewswire
Cognition Therapeutics Presented Data at Association for Research in Vision and Ophthalmology Showing Impact on Retinal Cell Health - Stock Titan
zervimesine shows promise in dry AMD trial - Investing.com
Cognition Therapeutics Reports Q1 2025 Financials and Progress - TipRanks
Cognition Therapeutics Inc Azioni (CGTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.10%
1.57%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):